BioCardia (BCDA) vs Palatin Technologies (PTN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palatin Technologies (PTN) has outperformed BioCardia (BCDA) over the past year, gaining 25.3% versus a loss of 25.4%. Over five years, BCDA leads with a -97.6% price change compared with -98.3% for PTN. BioCardia is the larger company by market cap ($16.0 million vs $16.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | PTN |
|---|---|---|
| Share price | $1.06 | $9.01 |
| Market cap | $16.05M | $16.05M |
| 1-day change | -2.75% | -5.36% |
| YTD return | -15.20% | -41.42% |
| 1-year return | -25.35% | +25.31% |
| 5-year return | -97.59% | -98.32% |
| EPS (TTM) | $-0.64 | $-2.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $31.00 |
| 52-week low | $0.75 | $5.61 |
| Distance from 52-week high | -41.11% | -70.94% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1362.26% | +493.78% |
| Average volume | 282.05K | 62.48K |
| Shares outstanding | 15.14M | 1.78M |
| Employees | 17 | 25 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTN has outperformed BCDA by 50.7 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Healthcare · Biotechnology · 25 employees
BCDA vs PTN FAQ
Which is bigger, BioCardia or Palatin Technologies?
BioCardia (BCDA) is larger, with a market capitalization of $16.05M compared with $16.05M for Palatin Technologies (PTN).
Which stock has performed better over the past year, BCDA or PTN?
PTN returned +25.31% over the past 12 months, compared with -25.35% for BCDA (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Palatin Technologies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.